The role of stem-cell transplantation in the treatment of marginal zone lymphoma

Avichai Shimoni

Research output: Contribution to journalReview articlepeer-review


High-dose chemotherapy and autologous stem-cell transplantation (ASCT) is standard therapy in relapsed/refractory aggressive lymphoma. The optimal therapy of relapsed/refractory disseminated marginal-zone lymphoma (MZL) has not been defined. Limited data on ASCT in this setting suggests outcomes are similar to what is expected in follicular lymphoma. International guidelines suggest that ASCT should be considered in follicular lymphoma in second or subsequent remission, in particular in high-risk disease, or following disease transformation. These guidelines can be extrapolated to MZL. ASCT is not considered curative but a subset of patients achieve very long remissions. The major concern is the occurrence of secondary malignancies possibly related to total-body irradiation. Allogeneic SCT is usually considered after failure of ASCT, but can also be considered upfront in younger patients seeking curative approach. The introduction of novel/targeted therapies may change the role and timing SCT may have in the treatment algorithm of indolent lymphomas.

Original languageEnglish
Pages (from-to)166-171
Number of pages6
JournalBest Practice and Research in Clinical Haematology
Issue number1-2
StatePublished - 1 Mar 2017


  • Marginal-zone lymphoma
  • Stem-cell transplantation


Dive into the research topics of 'The role of stem-cell transplantation in the treatment of marginal zone lymphoma'. Together they form a unique fingerprint.

Cite this